相关实验视频
Updated: May 17, 2025

Culture of Bladder Cancer Organoids as Precision Medicine Tools
Published on: December 28, 2021
膀癌的发病率,医疗保健途径和经济负担:来自法国国家医疗保健系统数据库的现实世界观察研究
Aldéric Masoandro Fraslin1, Simone Benhamou1, Thierry Lebret2
1Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France; University Paris-Saclay, Oncostat U1018, INSERM, Labeled Ligue Contre le Cancer, Villejuif, France.
这项研究分析了法国膀癌 (BC) 发病率,发现 TURBT 是最常见的初始治疗. 医疗费用因治疗途径而异,系统性治疗是最昂贵的.
科学领域:
- 在瘤学瘤学.
- 卫生经济学 卫生经济学
- 公共卫生 公共卫生
背景情况:
- 膀癌 (BC) 是一个重大的公共卫生问题.
- 了解发病率,患者特征和医疗保健利用率对于资源配置和治疗优化至关重要.
- 以前的研究往往侧重于特定的治疗方式或地理区域,因此需要在法国进行国家一级的分析.
研究的目的:
- 为了确定法国膀癌 (BC) 的发病率.
- 描述被诊断为BC的患者,并在诊断后的第一年内界定他们的医疗保健途径.
- 估计与不同BC治疗策略相关的医疗成本.
主要方法:
- 利用法国国家医疗保健系统数据库来识别2017年初始BC诊断的成年患者.
- 根据接受的最具侵入性的外科手术程序 (例如,囊切除术,膀瘤通过尿道切除 (TURBT)) 来分类患者.
- 分析了使用等级分类的医疗保健途径,并估计了每个已识别的集群的医疗费用.
主要成果:
- 该研究包括24,737名发生BC患者,平均年龄为72岁,80.2%是男性.
- 膀瘤通过尿道切除 (TURBT) 单独是最常见的初始治疗方法 (38.4%),平均成本为4435.5欧元.
- 费用差异很大,从TURBT的6129欧元与内插入到25,636欧元的系统治疗后囊切除术.
结论:
- 这项研究提供了法国膀癌 (BC) 发病率的综合国家估计.
- 它阐明了各种医疗保健途径,并量化了与BC管理相关的经济负担.
- 调查结果强调了基于治疗强度的显著成本差异,为医疗保健政策和资源规划提供了信息.
相关概念视频
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Health Information Technology and Healthcare Information System
Health Information Technology, commonly called HIT, integrates advanced information systems and technology in healthcare settings. Its primary functions include:
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Preventive Healthcare Services
Prevalence and Incidence
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic
HAIs significantly increase the cost of health care. Extended stays in healthcare institutions, increased disability, increased costs of medications, including specialized antibiotics, and prolonged recovery times add to the patient's expenses and the healthcare institution and funding bodies.

